Shell Asset Management Co. Sells 2,992 Shares of Biogen Inc. $BIIB

Shell Asset Management Co. lowered its holdings in Biogen Inc. (NASDAQ:BIIB) by 35.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,448 shares of the biotechnology company’s stock after selling 2,992 shares during the period. Shell Asset Management Co.’s holdings in Biogen were worth $763,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of BIIB. Empowered Funds LLC raised its holdings in Biogen by 64.9% during the 1st quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock valued at $965,000 after acquiring an additional 2,777 shares during the period. Focus Partners Wealth boosted its holdings in shares of Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock worth $1,392,000 after acquiring an additional 6,436 shares during the period. Sivia Capital Partners LLC purchased a new position in shares of Biogen in the second quarter valued at $216,000. Sequoia Financial Advisors LLC raised its stake in shares of Biogen by 50.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 4,527 shares of the biotechnology company’s stock valued at $568,000 after purchasing an additional 1,510 shares during the period. Finally, Mutual Advisors LLC purchased a new stake in Biogen during the 2nd quarter worth about $234,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on BIIB shares. Mizuho lifted their target price on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a report on Tuesday, February 10th. Wolfe Research set a $231.00 price objective on shares of Biogen in a research note on Monday, February 9th. Guggenheim increased their target price on shares of Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Wells Fargo & Company raised their price target on shares of Biogen from $190.00 to $200.00 and gave the company an “equal weight” rating in a report on Sunday, February 8th. Finally, Morgan Stanley set a $190.00 price target on shares of Biogen in a research report on Sunday, February 8th. Twelve equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Biogen presently has an average rating of “Hold” and a consensus target price of $205.84.

Biogen Stock Performance

Biogen stock opened at $196.52 on Tuesday. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm has a market cap of $28.84 billion, a P/E ratio of 22.31, a P/E/G ratio of 1.56 and a beta of 0.16. Biogen Inc. has a 1-year low of $110.04 and a 1-year high of $202.41. The firm has a 50-day moving average of $178.54 and a 200-day moving average of $159.77.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The company had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the business earned $3.44 EPS. Biogen’s revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts expect that Biogen Inc. will post 15.83 EPS for the current year.

Insider Transactions at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.